Yes Execution of Ryoncil Approval and commercial phase execution leads to:
- US Ryoncil aGVHD use
- US Ryoncil Label Extension use - Adults etc
- US Ryoncil Off Label Use - ARDS, Chrons, IBD, MIS-C etc etc and etc…keep going.
- Parternship(s) for approval and distribution in Rest of World Countries. Japan already on board. Dozens of countries/regions to follow.
- Likely RoW use will accelerate the use of Ryoncil in even more inflammatory disease off label situation’s. That will take on a life of its own globally.
= Savings lots of lives and lots of revenues Worldwide
That is just Ryoncil …then we have on Rexy on the burst also …same, same and same commercial execution model.
June 24 - MSB % of portfolio AND + or - %, page-47
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 72752 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 205100 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |